Prostatype® – a new gene test for prostate cancer patients
In an external clinical validation study, 30 randomly chosen prostate cancer patients were tested with the Prostatype® Test System and the results were evaluated by an independent urologist. The Prostatype® Test System could confirm the original treatment choice in 23% of all cases and suggested a reassessment in 67% of all cases. This shows that 90% of patients would benefit from using the Prostatype® Test System.
Further clinical validation studies are in progress.